FDA's Division of Bioequivalence is requesting that companies submit potency data for both reference products and test products in all bio studies. According to the division, some firms only submit data on the potency of the test drug. When a product has too high or too low a blood level, the data can help determine whether a potency difference is causing the problem, the division said.
You may also be interested in...
The appointment of Belén Garijo as CEO of the German major from May next year is a small but significant step on the road to addressing gender inequality at the very top level of management in the world of big pharma.
The FDA has published fresh guidance taking a tougher stance on sponsor reasons for needing more time to respond to complete response letters.
Stada has named Yann Brun to become the group’s new head of global development, portfolio, regulatory and business development, replacing Robert Knerr. The move is the latest in a string of key appointments at Stada as the firm builds on a series of acquisitions and deals.